DrugPatentWatch Database Preview
ALECENSA Drug Profile
Which patents cover Alecensa, and when can generic versions of Alecensa launch?
Alecensa is a drug marketed by Hoffmann-la Roche and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-three patent family members in thirty-eight countries.
The generic ingredient in ALECENSA is alectinib hydrochloride. One supplier is listed for this compound. Additional details are available on the alectinib hydrochloride profile page.
Summary for ALECENSA
| International Patents: | 83 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 107 |
| Clinical Trials: | 9 |
| Patent Applications: | 50 |
| Drug Prices: | Drug price information for ALECENSA |
| DailyMed Link: | ALECENSA at DailyMed |
Generic Entry Opportunity Date for ALECENSA
Generic Entry Date for ALECENSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ALECENSA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Roche Pharma AG | Phase 2 |
| Instituto Nacional de Cancerologia de Mexico | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
Pharmacology for ALECENSA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
Synonyms for ALECENSA
| 1256580-46-7 |
| 1256580-46-7 , C30H34N4O2 , CH 5424802 , CH-5424802 |
| 1256589-74-8 |
| 1416163-60-4 |
| 3341AH |
| 4CA-0118 |
| 5H-Benzo[B]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-ipperidinyl]-11-oxo-, hydrochloride (1:1) |
| 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo- |
| 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-, hydrochloride (1:1) |
| 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-5h-benzo(b)carbazole-3-carbonitrile |
| 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3- |
| 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile |
| 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile hydrochloride |
| 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile hydrochloride (1:1) |
| 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrileCH5424802 |
| 9-Ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile |
| 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile monohydrochloride salt |
| 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazol-3-carbonitril |
| 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile |
| 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile |
| 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile |
| 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile |
| 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride |
| A8393 |
| AB0035866 |
| ABP000797 |
| AC-29020 |
| AC-29721 |
| ACN-050755 |
| AF 802 |
| AF 802|||CH 5424802 |
| AF-802 |
| AF-802 hydrochloride |
| AF802 |
| AGN-PC-09O9BF |
| AK170451 |
| AK174941 |
| AKOS025290737 |
| AKOS025404940 |
| Alecensa (TN) |
| Alectinib |
| Alectinib (CH5424802) |
| Alectinib (USAN/INN) |
| Alectinib [USAN:INN] |
| Alectinib Hydrochloride |
| Alectinib hydrochloride (JAN) |
| Alectinib Hydrochloride;AF-802 Hydrochloride;CH-5424802 Hydrochloride;RG-7853 Hydrochloride;RO-5424802 Hydrochloride |
| alectinib monohydrochloride |
| AOB87311 |
| AOB87772 |
| AS-17008 |
| AS-17062 |
| BC638868 |
| BCP02589 |
| BCP09075 |
| BCP9000514 |
| BDBM50362781 |
| C30H34N4O2 |
| C30H34N4O2.ClH |
| cc-247 |
| CH 5424802 |
| CH-5424802 |
| CH-5424802/RG-7853 |
| CH-5428402 HCl |
| CH5424802 |
| CH5424802 (Hydrochloride) |
| CH5424802 HCl |
| CH5424802 HCl salt, Alectinib HCl salt, AF802 HCl salt |
| CH5424802,CAS:1256580-46-7 |
| CH5424802(Alectinib) |
| CH5424802(Hydrochloride) |
| CH5424802/CH-5424802 |
| CHEBI:62268 |
| CHEBI:90936 |
| CHEMBL1738797 |
| CHEMBL3707320 |
| CS-0518 |
| CS-3480 |
| D10450 |
| D10542 |
| DB11363 |
| DTXSID10154841 |
| DTXSID50154840 |
| EMH |
| EX-A1553 |
| EX-A406 |
| FT-0748626 |
| GTPL7739 |
| GYABBVHSRIHYJR-UHFFFAOYSA-N |
| HY-13011 |
| HY-13011A |
| J-005256 |
| J-519506 |
| KB-76034 |
| KDGFLJKFZUIJMX-UHFFFAOYSA-N |
| KS-0000062Z |
| KS-00001D3B |
| LIJ4CT1Z3Y |
| MLS006010971 |
| MolPort-023-293-545 |
| MolPort-039-137-749 |
| NCGC00346688-01 |
| NCGC00346688-04 |
| P9YY73LO6J |
| QCR-83 |
| RL01191 |
| S-7691 |
| s2762 |
| SB16515 |
| SB16516 |
| SC-94173 |
| SCHEMBL14991271 |
| SCHEMBL896753 |
| SMR004702775 |
| UNII-LIJ4CT1Z3Y |
| UNII-P9YY73LO6J |
| Y0295 |
| ZINC66166864 |
US Patents and Regulatory Information for ALECENSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ALECENSA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1179878 | Start Trial |
| Japan | 4918630 | Start Trial |
| Russian Federation | 2013112011 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALECENSA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2441753 | PA2017017 | Lithuania | Start Trial | PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216 |
| 2441753 | CA 2017 00024 | Denmark | Start Trial | PRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/16/1169/01 20170220 |
| 2441753 | 1790024-2 | Sweden | Start Trial | PRODUCT NAME: ALECTINIB OR SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/16/1169/001 20170220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
